Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioMarin Pharmaceutical
Pharma
BioMarin makes its largest transaction, paying $4.8B for Amicus
BioMarin has announced the largest transaction in the company’s 28-year history, ponying up $4.8 billion for fellow rare disease specialist Amicus.
Kevin Dunleavy
Dec 19, 2025 11:28am
BioMarin looks to drop hemophilia gene therapy Roctavian
Oct 28, 2025 11:49am
Inside the commercial growing pains of hemophilia gene therapies
Sep 12, 2025 10:00am
Fierce Biotech
Sanofi snags BioMarin leader to serve as CMO
Aug 26, 2025 11:06am
BioMarin touts pipeline asset as potential Voxzogo replacement
Aug 5, 2025 11:30am
BioMarin to add €60M lab to Irish manufacturing site
Dec 9, 2024 3:50pm
